Incyte (INCY) Share-based Compensation (2010 - 2026)
Incyte (INCY) reported Share-based Compensation of $64.1 million for Q1 2026, up 5.16% on a YoY basis from $61.0 million in Q1 2025, and up 3.17% quarter-over-quarter from $62.2 million in Q4 2025.
Incyte (INCY) Share-based Compensation (2010 - 2026) Analysis & Trends
Incyte has reported Share-based Compensation for 17 years, with the latest figure at $64.1 million in Q1 2026.
- For the quarter ending Q1 2026, Share-based Compensation rose 5.16% year-over-year to $64.1 million; the trailing twelve-month figure through Mar 2026 stood at $252.5 million (down 5.53% YoY), and the FY2025 full-year result was $249.3 million, down 6.28% from the prior year.
- Share-based Compensation for Q1 2026 stood at $64.1 million, up from $62.2 million in the prior quarter.
- The five-year high for Share-based Compensation was $77.9 million in Q3 2024, with the low at $43.8 million in Q1 2022.
- Historically, Share-based Compensation has averaged $57.9 million across 5 years, with a median of $59.8 million in 2024.
- Annual changes were most pronounced in 2024 — Share-based Compensation surged 62.34% — and 2025, when it slipped 20.95%.
- Incyte's Share-based Compensation stood at $52.7 million in 2022, then rose by 13.88% to $60.0 million in 2023, then gained by 19.55% to $71.7 million in 2024, then fell by 13.33% to $62.2 million in 2025, then gained by 3.17% to $64.1 million in 2026.
- The last three Share-based Compensation figures came in at $64.1 million (Q1 2026), $62.2 million (Q4 2025), and $61.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 64.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 64.13 Mn |
| Mar 31, 2026 | 64.13 Mn |
| Dec 31, 2025 | 62.16 Mn |
| Dec 31, 2025 | 62.16 Mn |
| Sep 30, 2025 | 61.60 Mn |
| Sep 30, 2025 | 61.60 Mn |
| Jun 30, 2025 | 64.61 Mn |
| Jun 30, 2025 | 64.61 Mn |
| Mar 31, 2025 | 60.98 Mn |
| Mar 31, 2025 | 60.98 Mn |
| Dec 31, 2024 | 71.72 Mn |
| Dec 31, 2024 | 71.72 Mn |
| Sep 30, 2024 | 77.92 Mn |
| Sep 30, 2024 | 77.92 Mn |
| Jun 30, 2024 | 56.64 Mn |
| Jun 30, 2024 | 56.64 Mn |
| Mar 31, 2024 | 59.78 Mn |
| Mar 31, 2024 | 59.78 Mn |
| Dec 31, 2023 | 59.99 Mn |
| Dec 31, 2023 | 59.99 Mn |